2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down with Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, fresh from his opening keynote at One Nucleus's landmark Genesis conference in London. Join us as Mike dissects the winners and losers reshaping pharma's landscape: Eli Lilly's historic as...
All content for BioBiz Buzz is the property of https://biobizbuzz.com/ and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down with Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, fresh from his opening keynote at One Nucleus's landmark Genesis conference in London. Join us as Mike dissects the winners and losers reshaping pharma's landscape: Eli Lilly's historic as...
The radioligand therapy market will be worth $42 billion by 2032. However, beneath the headline-grabbing acquisitions lies a complex web of technical and commercial challenges that threaten to limit patient access to these revolutionary cancer treatments. The path to successful radioligand development is fraught with obstacles, from the "melting ice cube" logistics of short-lived radioisotopes to the renal toxicity pitfalls that plague small-molecule approaches. In this episode of BioBiz Buzz...
BioBiz Buzz
2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down with Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, fresh from his opening keynote at One Nucleus's landmark Genesis conference in London. Join us as Mike dissects the winners and losers reshaping pharma's landscape: Eli Lilly's historic as...
